
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Pharmaceutical Technology Europe
Click the title above to open the Pharmaceutical Technology Europe January 2013 issue in an interactive PDF format.
almost 14 years ago
Pharma Never Diesalmost 14 years ago
A Look Ahead at Manufacturing and Regulationalmost 14 years ago
Aseptic Processing: A Primeralmost 14 years ago
Manufacturing Misery in Vaccinesalmost 14 years ago
Product Spotlight





